Tokyo, June 22 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061995) titled 'A Multicenter Retrospective Study of Neoadjuvant Therapy for Biological Borderline Resectable Pancreatic Cancer' on June 22.
Study Type:
Observational
Primary Sponsor:
Institute - Osaka University
Condition:
Condition - Pancreatic invasive ductal adenocarcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to evaluate the current practice of neoadjuvant therapy in patients with biological borderline resectable pancreatic cancer with elevated CA19-9 levels and to provide insights into the development of optimal neoadjuvant treatment strategies for this condition.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with biological borderline resectable pancreatic cancer with elevated CA19-9 levels (>500 U/mL) who underwent pancreatic resection following neoadjuvant therapy between January 1 2012 and December 31 2023.
Key exclusion criteria - Patients who opted out of participation in this study.
Target Size - 220
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 06 Month 09 Day
Date of IRB - 2026 Year 06 Month 10 Day
Anticipated trial start date - 2026 Year 07 Month 01 Day
Last follow-up date - 2029 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070936
Disclaimer: Curated by HT Syndication.
